Regeneron has two classes of stock and only one of them trades: the common stock, listed on the Nasdaq Global Select Market as REGN and available through any broker with Nasdaq access. Behind the ticker sit two kinds of revenue: medicines Regeneron sells itself, led by its EYLEA eye injections in the US, and profit shares from partners, above all on Dupixent, which Sanofi records worldwide. This guide explains that split, the order and the filing dates worth following.
What Does Regeneron Do?
Regeneron Pharmaceuticals' 10-K calls it "a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases." It was incorporated in New York in January 1988, went public in April 1991 and is based in Tarrytown, New York, with plants in Rensselaer, New York, and Limerick, Ireland. The 10-K says its VelocImmune mouse platform "is utilized to produce fully human antibodies."
EYLEA HD and EYLEA (aflibercept) treat retinal diseases such as wet age-related macular degeneration and diabetic macular edema; the FDA approved the higher-dose EYLEA HD in August 2023. Regeneron sells both in the US and Bayer sells them elsewhere. Dupixent (dupilumab), developed with Sanofi, is approved for conditions including atopic dermatitis, asthma and chronic obstructive pulmonary disease. Libtayo (cemiplimab) is a cancer immunotherapy used in lung cancer and some skin cancers. Smaller products include the cholesterol drug Praluent and Lynozyfic for multiple myeloma, and the October 2026 results release counted about 50 product candidates in clinical development.
How Regeneron Makes Money
Regeneron sells some medicines itself, takes a share of the profits on medicines its partners sell, and collects royalties. In 2025 the split was:
| Revenue line | What it covers | Share of 2025 revenue |
|---|---|---|
| EYLEA HD and EYLEA, US | Eye injections sold by Regeneron | 30.6% |
| Libtayo, global | Cancer medicine sold by Regeneron | 10.1% |
| Other product sales | Praluent, Evkeeza and smaller products | 3.3% |
| Sanofi collaboration | Profit share on Dupixent and Kevzara, plus supply | 41.0% |
| Bayer collaboration | Profit share on the eye drugs outside the US, plus supply | 9.9% |
| Other revenue | Royalties, licensing and contract manufacturing | 5.1% |
Percentages are calculated from the fiscal 2025 amounts in the 10-K, rounded to one decimal.
Total revenue rose only about 1% in 2025 because the biggest lines moved apart. US sales of the original EYLEA fell about 42%, which the 10-K puts down to competition, patients lost to compounded bevacizumab "due to patient affordability constraints," the switch to EYLEA HD and a lower net price. EYLEA HD's US sales rose about 36%, and Dupixent's global net sales about 26%.
The Sanofi line follows a formula. The partners split Dupixent profits in the US equally; outside the US, Regeneron's share rises with sales on a sliding scale from 35% to 45%. Part of that share went back to Sanofi to repay development costs Sanofi had funded, until the balance was fully repaid as of 30 June 2026. In the third quarter of 2026 Regeneron's profit share reached 38% of Dupixent and Kevzara net sales, against 29% a year earlier, and total revenue grew 36%. Bayer, for its part, shares profits on the eye drugs outside the US equally, and two distributors took 77% of Regeneron's gross product revenue in 2025.
REGN Stock at a Glance
| Item | Detail |
|---|---|
| Exchange | Nasdaq Global Select Market |
| Ticker | REGN |
| Security | Common stock, the sole 12(b) registration on the 10-K cover |
| Other share class | Class A stock, ten votes per share, not traded |
| Sector | Biotechnology |
| Index membership | S&P 500 and Nasdaq-100 |
| Headquarters | Tarrytown, New York |
| Incorporated | New York, January 1988 |
| Fiscal year | Calendar year, ending 31 December |
| Dividend policy | Paid quarterly since 2025, alongside buybacks |
| SEC identifier | CIK 872589 |
Price and market value move all day; the Regeneron stock page on Bitbase shows them live.
How to Buy Regeneron Stock
REGN is a US company's listed common stock, with no depositary receipt in between, and the Class A shares cannot be bought at all. The steps:
1. Open an account with a broker that reaches Nasdaq, and note who holds your assets and which authority oversees that firm.
2. Pass the identity checks. Non-US individuals usually complete IRS Form W-8BEN, which documents that they are not US persons for tax.
3. Deposit money. Converting from another currency adds a cost of its own.
4. Search for REGN and confirm the result reads Regeneron Pharmaceuticals common stock on Nasdaq.
5. Pick an order type and size. A market order fills at the best available price; a limit order sets a maximum and may not fill. Some brokers sell fractional shares on their own terms.
Outside the United States, the dividend brings US tax into play. The IRS states that "most types of U.S. source income received by a foreign person are subject to U.S. tax of 30%," and that "a reduced rate, including exemption, may apply" under a tax treaty. Your home country may tax the income again.
Via index funds, Regeneron comes bundled with many other companies: any fund that fully replicates the S&P 500 or the Nasdaq-100 owns it, and State Street's SPY showed it in holdings dated 29 October 2026.
What Moves REGN Stock
The EYLEA handover. Each quarter shows how fast patients move to EYLEA HD and how much biosimilars take. Amgen's biosimilar Pavblu launched in the US in the fourth quarter of 2024, and the 10-K expects that competition to keep increasing. EYLEA HD's US sales rose 62% in the third quarter of 2026, and Regeneron is working toward FDA approval of a pre-filled syringe by the end of 2026.
Patent disputes. Regeneron is suing Amgen in the US over its aflibercept biosimilar, and Amgen counterclaims that some Regeneron patents are unenforceable; a claim construction hearing is set for 1 December 2026. A US review of an EYLEA HD patent, requested by Alvotech, has oral argument on 4 December 2026. Patent expiries can reshape a drugmaker's revenue quickly, as the Pfizer stock guide shows for Eliquis and Ibrance.
Dupixent and the Sanofi terms. The 10-K lists Dupixent's main US composition-of-matter patent, extended, to March 2031. In October 2026 the partners agreed to co-develop four new long-acting Regeneron antibodies aimed at IL-4, IL-13 and the IL-4 receptor, sharing global profits equally with Sanofi leading commercialization. Sanofi's up-front payment is to be booked as revenue in the fourth quarter of 2026.
Regulatory dates. The October 2026 release expected an FDA decision on cemdisiran in generalized myasthenia gravis in November 2026 and set target dates in early 2027 for Ordspono and Libtayo.
US drug pricing. Under agreements announced in April 2026, Regeneron will sell certain products to Medicaid at prices no higher than a benchmark set against other developed countries. The same agreements shield its products from tariffs stemming from a Section 232 investigation through January 2029, provided it keeps its US investment commitments.
Caveats Before Owning REGN
Item 1A of the 10-K lists many risks; five bear most on a REGN share.
Concentration. "We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent."
Competition. Rival products, biosimilars included, "may be superior to, or more established or cost effective than" Regeneron's own.
Partners. If the collaborations with Sanofi or Bayer "are terminated or breached," its ability to develop and sell certain products "may be materially harmed."
Manufacturing. Failures at the Rensselaer and Limerick plants or elsewhere in the supply chain "would adversely affect our ability to supply our products."
Volatility and control. "Our stock price is extremely volatile," and Class A holders, with ten votes a share, held 14.9% of the combined voting power at the end of 2025.
Above the business sits single-stock risk. The dividend is new and discretionary, with "no assurance" that it will be maintained, and currency moves can change what a non-US holder actually receives.
How to Research REGN Yourself
Regeneron's filings are on EDGAR under CIK 872589: a 10-K each year, 10-Qs for the first three quarters and 8-Ks for events such as quarterly results and the October 2026 Sanofi amendment. In the 10-K, Item 1 holds the product, pipeline and patent tables, risk factors sit in Item 1A, and the notes split revenue by product and partner. Each 10-Q also reports Dupixent and Kevzara net sales as recorded by Sanofi, with Regeneron's profit share. Other listed companies are a click away in the list of US stock pages on Bitbase.
Regeneron Stock FAQ
Does Regeneron pay a dividend?
Yes. The 10-K states: "In 2025, we initiated a quarterly cash dividend program." The third-quarter 2026 10-Q records a dividend declared in each quarter of 2026 so far, plus one in October; each needs board approval.
Can I buy Regeneron stock with crypto?
Not directly. Nasdaq trades are paid for in US dollars, so the crypto has to be converted to cash and transferred to a broker before any REGN order, and that conversion may be taxable where you live. A walkthrough of buying stocks with crypto explains each step.
Is REGN in the S&P 500 and the Nasdaq-100?
It is in both: Nasdaq's constituent list dated 29 October 2026 includes Regeneron, and SPY's holdings of the same date list it too.
What is Regeneron's Class A stock?
A second class held, the 10-K says, generally by shareholders who bought before the IPO. Each Class A share carries ten votes, converts into common stock share for share and can pass only to permitted transferees. It does not trade, so REGN is the share outside investors buy.
Does Regeneron or Sanofi sell Dupixent?
Both promote it in the US and some other countries, but Sanofi records the global net sales and Regeneron books its profit share as collaboration revenue.
Conclusion
Placing the order is the quick part, needing only Nasdaq access, the REGN ticker and a market or limit order. Understanding the business takes longer: an eye franchise moving to EYLEA HD under biosimilar pressure, a Dupixent profit share that has just stepped up, and FDA and court dates into early 2027. Start with the latest 10-Q before deciding how much one biotech company should weigh in a portfolio.
Related reading
Other Bitbase articles on this topic:
- How to Buy Novo Nordisk Stock (NVO): ADR, Wegovy and Ozempic
- How to Buy Sanofi Stock (SNY): Half-Share ADS and Dupixent
- How to Buy Takeda Stock (TAK): Two ADSs per Share, Entyvio
Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of October 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.
References
[1] Regeneron Pharmaceuticals Form 10-K, fiscal 2025 (SEC EDGAR) www.sec.gov
[2] Regeneron Pharmaceuticals Form 10-Q, quarter ended 30 September 2026 (SEC EDGAR) www.sec.gov
[3] Regeneron third-quarter 2026 results release, 30 October 2026 (SEC EDGAR) www.sec.gov
[4] Regeneron Pharmaceuticals Form 8-K, October 2026: Sanofi collaboration amendment (SEC EDGAR) www.sec.gov
[5] Regeneron Pharmaceuticals Form 10-K, fiscal 2001: incorporation and IPO (SEC EDGAR) www.sec.gov
[6] Nasdaq: Nasdaq-100 index constituents www.nasdaq.com
[7] State Street SPDR S&P 500 ETF Trust (SPY): daily holdings www.ssga.com
[8] IRS: NRA Withholding www.irs.gov






